Familial Hyperglucagonemia — An Autosomal Dominant Disorder

New England Journal of Medicine

Volumn 296, Issue 10, 1977, Pages 534-538

  Boden, Guenther ^a   Owen, Oliver E ^a  

^a Temple University Health Sciences Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GLUCAGON; GLUCOSE; GLYCOGEN;

ANEMIA; AUTOSOMAL DOMINANT INHERITANCE; BODY WEIGHT; DERMATITIS; DIABETES MELLITUS; DIAGNOSIS; ETIOLOGY; GLUCAGONOMA; HYPERGLUCAGONEMIA; MAJOR CLINICAL STUDY; PEDIGREE; SIBLING;

EID: 0017365586     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM197703102961003     Document Type: Article

References (32)

1. Becker SW, Kahn D, Rothman S: Cutaneous manifestations of internal malignant tumors. Arch Dermatol Syphiligr 45: 1069–1080, 1942
2. McGavran MH, Unger RH, Recant L, et al: A glucagon-seereting alpha-cell carcinoma of the pancreas. N Engl J Med 274: 1408–1413, 1966
3. Mallinson CN, Bloom SR. Warin AP, el al: Glucagonoma syndrome. Lancet 2: 1–5, 1974
4. Leichter SB, Pagliara AS, Greider MH, et al Uncontrolled diabetes mellitus and hyperglucagonemia associated with an islet cell carcinoma. Am J Med 58: 285–293, 1975
5. Croughs RJM, Hulsmans HAM, Israël DE, et al: Glucagonoma as part of the polyglandular adenoma syndrome. Am J Med 52: 690–698, 1972
6. Case Records of the Massachusetts General Hospital (Case 20–1975). N Engl J Med 292: 1117–1123, 1975
7. Danforth DN Jr, Triche T, Doppman JL, et al: Elevated plasma proglucagon-like component with a glueagon-secreting tumor: effect of streptozotocin. N Engl J Med 295: 242–245, 1976
8. Tiengo A, Fedele D, Marchiori E, et al: Suppression and stimulation mechanisms controlling glucagon secretion in a case of islet-cell tumor producing glucagon, insulin and gastrin. Diabetes 25: 408–412, 1976
9. Boden G, Owen OE, Rezvani 1, et al: An islet cell carcinoma secreting glucagon and insulin. Diabetes (in press)
10. Faloona GR, Unger RH: Glucagon, Methods of Hormone Radioimmunoassay. Edited by BM Jaffe, HR Behrman. New York, Academic Press, 1974, pp 317–330
11. Soeldner JS, Slone D: Critical variables in the radioimmunoassay of serum insulin using double antibody technic. Diabetes 14: 771–779, 1966
12. Hill JB, Kessler G: An automated determination of glucose utilizing a glucose oxidase-peroxidase system. J Lab Clin Med 57: 970–980, 1961
13. Wahlberg F: Intravenous glucose tolerance in myocardial infarction, angina pectoris and intermittent claudication. Acta Med Scand [Suppl] 453: 7–93, 1966
14. Unger RH, Lefebvre PJ: Glucagon physiology, Glucagon: Molecular physiology: Clinical and therapeutic implications. Edited by PJ Lefebvre, RH Unger. New York, Pergamon Press, 1972, pp 213–244
15. Müller WA, Faloona GR, Aguilar-Parada E, et al: Abnormal alpha-cell function in diabetes: response to carbohydate and protein ingestion. N Engl J Med 283: 109–115, 1970
16. Rocha DM, Santeusanio F, Faloona GR, et al: Abnormal pancreatic alpha-cell function in bacterial infections. N Engl J Med 288: 700–703, 1973
17. Unger RH, Aguilar-Parada E, Müller WA, et al: Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 49: 837– 848, 1970
18. Aguilar-Parada E, Eisentraut AM, Unger RH: Effects of starvation on plasma pancreatic glucagon in normal man. Diabetes 18: 717–723, 1969
19. Ahlborg G, Felig P, Hagenfeldt L, et al: Substrate turnover during prolonged exercise in man: splanchnic and leg metabolism of glucose, free fatty acids and amino acids. J Clin Invest 53: 1080–1090, 1974
20. Aguilar-Parada E, Eisentraut AM, Unger RH: Pancreatic glucagon secretion in normal and diabetic subjects. Am J Med Sci 257: 415–419, 1969
21. Bilbrey GL, Faloona GR, White MG, et al: Hyperglucagonemia of renal failure. J Clin Invest 53: 841–847, 1974
22. Sherwin RS, Bastl C, Finkelstein FO, et al: Influence of uremia and hemodialysis on the turnover and metabolic effects of glucagon. J Clin Invest 57: 722–731, 1976
23. Gabbay KH, DeLuca K, Fisher JN Jr, et al: Familial hyperproinsulinemia: an autosomal dominant defect. N Engl J Med 294: 911–915, 1976
24. Valverde I, Villanueva ML, Lozano I, et al: Presence of glucagon immunoreactivity in the globulin fraction of human plasma (“big plasma glucagon”). J Clin Endocrinol Metab 39: 1090–1098, 1974
25. Valverde I, Lemon HM, Kessinger A, et al: Distribution of plasma glucagon immunoreactivity in a patient with suspected glucagonoma. J Clin Endocrinol Metab 42: 804–808, 1976
26. Weir GC, Knowlton SD, Martin DB: High molecular weight glucagon-like immunoreactivity in plasma. J Clin Endocrinol Metab 40: 296, 1975
27. Kuku SF, Jaspan JB, Emmanouel DS, et al: Heterogeneity of plasma glucagon: circulating components in normal subjects and patients with chronic renal failure. J Clin Invest 58: 742–750, 1976
28. Palmer.JP, Werner PL, Benson JW: Dominant inheritance of large molecular weight glucagon (IRG). Diabetes 25: Suppl 1:326, 1976
29. Larsson LI, Grimelius L, Håkanson R, et al: Mixed endocrine pancreatic tumors producing several peptide hormones. Am J Pathol 79: 271– 284, 1975
30. Ballard HS, Frame B, Hartsock RJ: Familial multiple endocrine adenoma-peptic ulcer complex. Medicine (Baltimore) 43: 481–515, 1964
31. Steiner AL, Goodman AD, Powers SR: Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing's disease: multiple endocrine neoplasia, Type 2. Medicine (Baltimore) 47: 371–409, 1968
32. Moldawer MP, Nard GL, Raker JW: Concomitance of multiple adenomas of the parathyroids and pancreatic islets with tumor of the pituitary: a syndrome with familial incidence. Am J Med Sci 228: 190–206, 1954